An additional copy of the beta-amyloid precursor protein (APP) gene causes early-onset Alzheimer's disease (AD) in trisomy 21 (DS). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Amyloid beta protein (Abeta), the major component of neuritic plaques in Alzheimer's disease (AD), is derived from APP by sequential cleavages of beta- and gamma-secretases. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
On average, the accuracy of our step length estimation was about 98%. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
New technologies have considerable potential to support people with semantic dementia-a form of progressive aphasia-in their everyday lives, but evidence is still sparse. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The detection of nucleic acids by the innate immune system is an essential host response during viral infection. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
35/100
Autosomal dominant Alzheimer disease (ADAD) is caused by pathogenic variants in the APP, PSEN1 and PSEN2 genes, but a substantial fraction of reported variants is of unknown clinical significance. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Age was similar between groups (p = 0.07). 5 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a substantial public health issue with increasing prevalence globally. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a debilitating disease that leads to a gradual loss of memory and other cognitive abilities and tends to develop in people over 60 years of age. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Alzheimer's disease (AD) is recognized as one of the most common neurodegenerative causes of dementia worldwide, having been characterized by progressive cognitive decline for the most part. 2 key findings →
Participants: 461 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Three blood gene expression datasets of high dimensionality and low sample size (HDLSS) have been utilized in this study, with one dataset exhibiting significant class imbalance. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Accurate prediction of the progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) is essential for early intervention and effective disease management. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
35/100
Clinical investigations have suggested a potential link between cataracts and Alzheimer's disease (AD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Early and accurate diagnosis of dementia is essential to improving patient outcomes and reducing societal burden. 1 key finding →
Participants: 164 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Falls are a leading cause of morbidity and mortality in older adults, especially among nursing home residents. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In this update, we examine a checklist for real-world evidence use in Medicare drug price negotiations under the Inflation Reduction Act, a review of health technology assessment reassessments across major health technology assessment agencies, and two complementary studies that used natural experiment approaches to explore the relationship between herpes zoster vaccination and reduced dementia risk. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Down syndrome (DS) patients suffer from mental retardation, but also display enhanced beta-APP production and develop cortical amyloid plaques at an early age. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
BACE2 is homologous to BACE1, a beta-secretase that is involved in the amyloidogenic pathway of amyloid precursor protein (APP), and maps to the Down syndrome critical region of chromosome 21. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our study highlights the potential of Decipher‐AI for screening undiagnosed cognitive impairment in primary care. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The global increase in dementia cases, which is predicted to exceed 152 million by 2050, poses substantial challenges to healthcare systems and caregiving structures. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
• AT use was limited and AT type used varied by caregiver living arrangement. • Most used ATs: daily living support and risk prevention; risk response least used. • Daily living support ATs linked to fewer care hours. • Risk prevention ATs tied to longer PT, higher CarerQol-7D, and lower SRB scores. • Daily support and risk response ATs most likely to extend PT by over six months. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia, a complex and debilitating spectrum of neurodegenerative diseases, presents a profound challenge in the quest for effective treatments. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
34/100
Digital health innovations hold diagnostic and therapeutic promise but may be subject to biases for underrepresented groups. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The early diagnosis of dementia, a progressive condition impairing memory, cognition, and functional ability in older adults, is essential for timely intervention and improved patient outcomes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
10 of the 1,102 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Potential value and impact of data mining and machine learning in clinical diagnostics
- Anthocyanin-enriched bilberry and blackcurrant extracts modulate amyloid precursor protein processing and alleviate behavioral abnormalities in the APP/PS1 mouse model of Alzheimer's disease
- Diagnostic value of digital clock drawing test in comparison with CERAD neuropsychological battery total score for discrimination of patients in the early course of Alzheimer's disease from healthy individuals
- Sleep Quality of Persons with Dementia and Family Caregivers in Korean Americans: Wearable Technology to Study the Dyadic Association
- Developing a machine learning model for detecting depression, anxiety, and apathy in older adults with mild cognitive impairment using speech and facial expressions: A cross-sectional observational study
- Virtual Reality for Therapeutic Recreation in Dementia Hospice Care: A Feasibility Study
- Unlocking Sensitive Data with SPHERE in the Age of AI
- Using Wearable Sensors to Measure and Predict Personal Circadian Lighting Exposure in Nursing Home Residents: Model Development and Validation
- Rapid Biomarker Screening of Alzheimer's Disease by Interpretable Machine Learning and Graphene-Assisted Raman Spectroscopy
- Navigating next-gen nutrition care using artificial intelligence-assisted dietary assessment tools—a scoping review of potential applications
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →